NASDAQ · Biotechnology

Enlivex Ltd. (ENLV) Stock

$0.17 -2.65% NASDAQ: ENLV Healthcare

Valuation

Metric	Value
Price	$0.17
Market Cap	$2.84M
P/E Ratio	0.03
P/B Ratio	0.01
P/S Ratio	0.00
EPS (TTM)	$25.48
52-Week High	$27.15
52-Week Low	$0.17
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	279.88%
ROA	83.82%
ROCE	-0.42%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	193.67

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-19.0M	$-26.0M	$-29.0M	$-16.0M	$-15.0M
Net Profit	$-14.0M	$-31.0M	$-29.0M	$-15.0M	$1.2B
EPS	$-8.10	$-34.65	$-23.40	$-10.95	$382.20
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$95.0M	$68.0M	$37.0M	$28.0M	$2.3B
Total Liabilities	$10.0M	$11.0M	$7.0M	$4.0M	$392.0M
Cash	$11.0M	$50.0M	$1.0M	$3.0M	$2.0M
Borrowings	$6.0M	$5.0M	$1.0M	$1.0M	$1.0M

Latest News

Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis MT Newswires · Jun 15, 2026 Enlivex advances Allocetra while expanding into prediction markets Proactive · May 11, 2026 Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress GlobeNewswire · Apr 23, 2026 H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook Insider Monkey · Apr 21, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-18.0M	$-24.0M	$-24.0M	$-13.0M	$-10.0M
Investing Cash Flow	$-40.0M	$54.0M	$-26.0M	$9.0M	$-1.0M
Financing Cash Flow	$8.0M	$0	$0	$0	$0
Net Cash Flow	$5.0M	$39.0M	$-49.0M	$3.0M	$-1.0M
Free Cash Flow	$-19.0M	$-32.0M	$-24.0M	$-13.0M	$-10.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.92
FCF Yield	-248.11%
Quick Ratio	119.39
Interest Coverage	-15.46
Return 1Y	-67.59%
Return 3Y	-83.25%
Return 5Y	-94.66%

About Enlivex Ltd.

Enlivex Ltd. is led by CEO Oren Hershkovitz, employs 71 people, headquartered in IL, publicly traded since 2014.

Enlivex Ltd. (ENLV) stock trades at $0.17 with a market capitalization of $2.84M. The stock is valued at a price-to-earnings (P/E) ratio of 0.03, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.17 and $27.15, and currently trades 99.4% below its 52-week high.

On profitability, Enlivex Ltd. generates a return on equity (ROE) of 279.88%, above the typical market range of roughly 12-15%, return on capital employed of -0.42%.

Enlivex Ltd. by the numbers, 2016–2025

Between 2016 and 2025 Enlivex Ltd. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit rose to $1.2B.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $4.1B.

Borrowings stand at $1.0M, cash from operations was $-10.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -33.2% over five years, and was 63.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Enlivex Ltd. (ENLV) — frequently asked questions

What is Enlivex Ltd. (ENLV) stock price today?

Enlivex Ltd. (ENLV) is currently trading at $0.17, down 2.65% today.

What is ENLV P/E ratio?

Enlivex Ltd.'s P/E ratio is 0.03. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.

What is ENLV return on equity (ROE)?

Enlivex Ltd.'s return on equity (ROE) is 279.88%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.

What is Enlivex Ltd.'s market cap?

Enlivex Ltd. has a market capitalization of $2.84M.

Does ENLV pay a dividend?

Enlivex Ltd. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does ENLV carry?

Enlivex Ltd. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is ENLV's profit margin?

Enlivex Ltd. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is ENLV in?

Enlivex Ltd. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is ENLV listed on?

Enlivex Ltd. trades on NASDAQ under the ticker ENLV.

What is ENLV's 52-week range?

Over the last year Enlivex Ltd. has traded between $0.17 and $27.15.

Related Healthcare Stocks

LLY Eli Lilly and Company $1275.99 +0.20% JNJ Johnson & Johnson $265.85 +0.77% ABBV AbbVie Inc. $286.55 +0.32% UNH UnitedHealth Group Incorporated Common Stock (DE) $412.19 -1.41% MRK Merck & Company, Inc. Common Stock (new) $142.04 -2.22% NVS Novartis AG $153.41 +1.52% AZN AstraZeneca PLC $171.11 -0.22% TMO Thermo Fisher Scientific Inc $680.64 +1.01% AMGN Amgen Inc. $440.91 +0.38% GILD Gilead Sciences, Inc. $158.35 +1.48% ABT Abbott Laboratories $104.86 +1.11% NVO Novo Nordisk A/S $38.99 -0.15%

Screens ENLV currently matches

On the figures above, Enlivex Ltd. passes the filters for 4 of our ready-made screens, among them Penny Stocks, Stocks Under $1, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Penny Stocks Stocks Under $1 Debt Free Stocks Under $100 Nano Cap Stocks

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.